Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Updated Generic Sofosbuvir Availability and Price in India 15 June 2015
2018 IAS Brief Document Ending an Epidemic – Prioritizing People Who Inject Drugs in HCV elimination Efforts.
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Up dated Generic Sofosbuvir availability and Price in India – 18 May 2015
Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
